Meghan Joyce Biography and Net Worth

Director of Guardant Health

Meghan Joyce has served as a member of Guardant Health’s board of directors since August 2021. Ms. Joyce currently serves as an independent advisor to select high growth organizations in the healthcare and consumer space. Previously, from September 2019 to April 2022, Ms. Joyce served as Chief Operating Officer and Executive Vice President of Platform at Oscar Health, a high-growth health tech and health insurance company, where she led operations, technology, clinical, marketing, and new business lines. Prior to joining Oscar Health, from 2013 to 2019, Ms. Joyce has held several leadership roles at Uber Technologies, most recently as Regional General Manager of the United States and Canada. Ms. Joyce has previously served as a Senior Policy Advisor at the United States Department of the Treasury, an investor at Bain Capital, and a consultant at Bain & Company. Ms. Joyce serves on the board of the Boston Beer Company (SAM). She holds an M.B.A degree from Harvard Business School and an B.A. degree in History from Harvard College.

What is Meghan V. Joyce's net worth?: The estimated net worth of Meghan V. Joyce is at least $350,680.08 as of December 2nd, 2024. Ms. Joyce owns 7,548 shares of Guardant Health stock worth more than $350,680 as of March 25th. This net worth approximation does not reflect any other investments that Ms. Joyce may own. Learn More about Meghan V. Joyce's net worth.
How do I contact Meghan V. Joyce?: The corporate mailing address for Ms. Joyce and other Guardant Health executives is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. Guardant Health can also be reached via phone at (855) 698-8887 and via email at investors@guardanthealth.com. Learn More on Meghan V. Joyce's contact information.
Has Meghan V. Joyce been buying or selling shares of Guardant Health?: Meghan V. Joyce has not been actively trading shares of Guardant Health during the last quarter. Most recently, Meghan V. Joyce sold 100 shares of the business's stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $35.90, for a transaction totalling $3,590.00. Following the completion of the sale, the director now directly owns 7,548 shares of the company's stock, valued at $270,973.20. Learn More on Meghan V. Joyce's trading history.
Who are Guardant Health's active insiders?: Guardant Health's insider roster includes Derek Bertocci (CFO), Ian Clark (Director), Helmy Eltoukhy (CEO), Meghan Joyce (Director), Kumud Kalia (Insider), Samir Kaul (Director), Stanley Meresman (Director), Amelia Merrill (SVP), Amirali Talasaz (COO), and Musa Tariq (Director). Learn More on Guardant Health's active insiders.
Are insiders buying or selling shares of Guardant Health?: During the last year, insiders at the sold shares 8 times. They sold a total of 5,880 shares worth more than $193,244.76. The most recent insider tranaction occured on March, 19th when Director Musa Tariq sold 116 shares worth more than $5,069.20. Insiders at Guardant Health own 5.5% of the company. Learn More about insider trades at Guardant Health.
Information on this page was last updated on 3/19/2025.

Meghan V. Joyce Insider Trading History at Guardant Health

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/2/2024	Sell	100	$35.90	$3,590.00	7,548
11/13/2024	Sell	2,896	$29.90	$86,590.40	7,648
6/4/2024	Sell	100	$27.87	$2,787.00	4,621
3/4/2024	Sell	100	$19.05	$1,905.00	4,521
12/4/2023	Sell	100	$26.34	$2,634.00	4,422
9/5/2023	Sell	100	$35.01	$3,501.00	4,323
6/15/2023	Sell	2,766	$37.55	$103,863.30	4,224

Meghan V. Joyce Buying and Selling Activity at Guardant Health

Guardant Health Company Overview

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Today's Range

Now: $46.46

$45.96

$47.70

50 Day Range

MA: $44.20

$35.84

$49.94

2 Week Range

Now: $46.46

$15.81

$50.89

Volume

1,304,391 shs

Average Volume

2,147,558 shs

Market Capitalization

$5.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.5